Prediction of the effect of metformin treatment in patients with polycystic ovary syndrome.

Abstract

The objective of the study was to find predictors of a successful therapy with metformin in polycystic ovary syndrome. 24 women with polycystic ovary syndrome were examined (oral glucose tolerance test and gonadotropin-releasing hormone analogue test) before and after a 6-month course of metformin (1 g/day). In 58% of the women, a significant improvement in the menstrual cycle pattern was observed. After a treatment course, a significant reduction in gonadotropin-releasing hormone analogue stimulated levels of testosterone (p < 0.05), free testosterone index (p < 0.01), luteinizing hormone (p < 0.05), and estradiol (p < 0.01) was found. The best prediction of the improvement in menstrual cyclicity after metformin was achieved with a combination of basal values of 17-hydroxyprogesterone, testosterone, sex hormone binding globulin, and androstenedione. These variables correctly classified 86.7% of the responders. The best predictor of changes in the index of free testosterone after metformin treatment was the combination of estradiol and androstenedione in the gonadotropin-releasing hormone analogue test, with basal testosterone correctly classifying 91.7% of the subjects.

• Authors: J Vrbíková, M Hill, L Stárka, K Vondra
• Journal: Gynecologic and obstetric investigation (Gynecol Obstet Invest) Vol. 53 Issue 2 Pg. 100-4 ( 2002) ISSN: 0378-7346 [Print] Switzerland
• PMID: 11961383 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2002 S. Karger AG, Basel

Chemical References

• Metformin

Topics

• Female
• Forecasting
• Humans
• Insulin Resistance
• Menstrual Cycle (drug effects)
• Metformin (therapeutic use)
• Polycystic Ovary Syndrome (drug therapy, physiopathology)